MIRA Pharmaceuticals Unveils Selective NMDA Binding Data for Ketamir-2

MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announces new preclinical data on Ketamir-2, a ketamine analog aimed at treating neurological disorders. The data highlight Ketamir-2's selective inhibition of the NMDA receptor, showing 30-50 times lower affinity for the PCP site compared to ketamine, which may reduce side effects like dissociation and hallucinations.

The benefits of this selective binding include reduced side effects, improved safety, and enhanced therapeutic effectiveness. Toxicology studies further validate Ketamir-2's safety profile, showing no toxicity at high doses in rats and dogs. Oral doses demonstrated significant antidepressant and anxiolytic activities at much lower concentrations, ensuring a substantial therapeutic window.

MIRA aims to submit an Investigational New Drug (IND) application to the FDA this year, potentially paving the way for clinical trials. If successful, Ketamir-2 could offer a new standard of care for conditions such as depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).